The United Kingdom and the United States have signed a landmark trade agreement that will guarantee zero import taxes on UK medicine shipments being sold in the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to boost expenditure on drugs through the National Health Service (NHS). This commitment guarantees that import taxes on these key products will stay at zero for a duration of the next three years.
This deal follows previous statements to dramatically increase tariffs on branded pharmaceutical products, with increases discussed reaching double the cost.
"This deal between the United Kingdom reinforces the international landscape for innovative medicines and introduces much-needed balance to transatlantic pharmaceutical trade," an announcement said.
Commercial Importance
Medicines represent one of the the United Kingdom's most significant exports to the US, which is easily the largest market for large companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period to the end of the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This deal safeguards jobs, boosts capital expenditure and facilitates the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Specific UK Commitments
The deal entails several specific commitments from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to increase overall NHS spending on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to control costs will be limited at 15%. Previously, repayments topped twenty percent.
Broader Context
This agreement comes amid a protracted row between the pharmaceutical industry and the ministers over medicine costs and regulatory access.
These tensions were intensified by assertions that American patients were paying several times more for the same drugs than patients in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar expansions have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a proportion of its resources over the previous ten-year period.
